The Pharmaceuticals & Biotechnology (PH&BIO) industry is part of the solution to global health challenges, with products and services that contribute to the social dimensions of the Sustainable Development Goals. It has a relatively large share of Prime-rated companies (27%).
In contrast to these social benefits, there is little evidence that the environmental risks of the PH&BIO industry’s operations and incidental activities are being actively managed, including challenges arising from water management due to pharmaceutical residues in the environment.
The PH&BIO industry is relatively less carbon intensive than other industries, but its impact is still significant, with the emission reduction approach of companies in the sector offering a key point of leverage for investors looking to take action on climate change.
Most of the severe controversies faced by the Pharmaceuticals & Biotechnology industry are high-profile cases involving anti-competitive behavior, bribery, consumer health, water pollution, and consumer rights.
Access to health care is a key risk for investors to monitor. Underserved populations often lack access to the beneficial products and services that the Pharmaceuticals & Biotechnology industry provides. The level of access to products and services impacts the industry’s absolute contribution to sustainable development.
Europe (UK): +44.20.3192.5799
Europe (Germany): +49.89.4622.48186
For General Inquiries
Inquiries about ISS’ products and services, requests for copies of proxy research reports, and requests to engage with ISS regarding research reports and policies should be directed to the Help Center.